IN2012CH05549A - - Google Patents

Download PDF

Info

Publication number
IN2012CH05549A
IN2012CH05549A IN5549CH2012A IN2012CH05549A IN 2012CH05549 A IN2012CH05549 A IN 2012CH05549A IN 5549CH2012 A IN5549CH2012 A IN 5549CH2012A IN 2012CH05549 A IN2012CH05549 A IN 2012CH05549A
Authority
IN
India
Prior art keywords
composition
ibuprofen
pharmaceutically acceptable
acceptable salt
active ingredient
Prior art date
Application number
Other languages
English (en)
Inventor
Prodduturi Dr Suneela
Chandra Illapakurthy Dr Ashok
Kumar Alluri Pavan
Kandarapu Dr Raghupathi
S Rudraraju Dr Varma
Original Assignee
Aizant Drug Res Solution Private Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aizant Drug Res Solution Private Ltd filed Critical Aizant Drug Res Solution Private Ltd
Priority to IN5549CH2012 priority Critical patent/IN2012CH05549A/en
Priority to PCT/IB2013/061370 priority patent/WO2014102745A1/en
Publication of IN2012CH05549A publication Critical patent/IN2012CH05549A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
IN5549CH2012 2012-12-31 2013-12-27 IN2012CH05549A (OSRAM)

Priority Applications (2)

Application Number Priority Date Filing Date Title
IN5549CH2012 IN2012CH05549A (OSRAM) 2012-12-31 2013-12-27
PCT/IB2013/061370 WO2014102745A1 (en) 2012-12-31 2013-12-27 High drug load ibuprofen sustained release composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN5549CH2012 IN2012CH05549A (OSRAM) 2012-12-31 2013-12-27

Publications (1)

Publication Number Publication Date
IN2012CH05549A true IN2012CH05549A (OSRAM) 2015-07-03

Family

ID=51019974

Family Applications (1)

Application Number Title Priority Date Filing Date
IN5549CH2012 IN2012CH05549A (OSRAM) 2012-12-31 2013-12-27

Country Status (2)

Country Link
IN (1) IN2012CH05549A (OSRAM)
WO (1) WO2014102745A1 (OSRAM)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201502077D0 (en) * 2015-02-09 2015-03-25 Cubic Pharmaceuticals Ltd And Delta Pharmaceuticals Ltd Improved hme technology
WO2019072877A1 (en) 2017-10-10 2019-04-18 Capsugel Belgium Nv GETTING MULTIPARTICULAR COMPOSITIONS

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US20080311162A1 (en) * 2007-05-16 2008-12-18 Olivia Darmuzey Solid form

Also Published As

Publication number Publication date
WO2014102745A1 (en) 2014-07-03

Similar Documents

Publication Publication Date Title
WO2015120110A3 (en) Novel pharmaceutical formulations
WO2015018380A3 (en) Therapeutic nanoparticles and the preparation methods thereof
MX2015016112A (es) Forma de dosificacion resistente al uso indebido que contiene una o mas particulas.
MX2013014788A (es) Liberacion modificada de 4-metil-3-[[4-(3-piridinl)-2-pirimidinil] -amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil ]-benzamida solubilizada utilizando acidos organicos.
MX2011007817A (es) Formulacion farmaceutica o alimenticia de liberacion controlada y proceso para su preparacion.
MX2013001677A (es) Formulaciones estables de linaclotida.
PH12015501096A1 (en) Composition for immediate and extended release
MX356111B (es) Composiciones farmaceuticas disuasorias de abuso, de liberacion inmediata.
GB2495676A (en) Use of binders for manufacturing storage stable formulations
PH12014502512A1 (en) Topical pharmaceutical compositions comprising terbinafine and urea
MY157673A (en) Pharmaceutical compositions comprising hydromorphone and naloxone
PH12012502082A1 (en) Combination of active loaded granules with additional actives
TN2015000135A1 (en) Modified release formulations for oprozomib
PH12016500865A1 (en) Composite formulation comprising tadalafil and amlodipine
WO2012085284A3 (en) High drug load pharmaceutical formulations comprising dronedarone and its pharmaceutically acceptable salts
MX2016001422A (es) Composicion farmaceutica de fingolimod.
WO2014056824A3 (en) Oral care composition
MX2014014579A (es) Composiciones farmaceuticas topicas de tipo emulsion aceite en agua que contienen un retinoide.
PH12015501377A1 (en) Solid unit with high fexofenadine content and process for the preparation thereof
WO2012085249A3 (en) Homogenous pharmaceutical oral dosage forms comprising lercanidipine and enalapril or their pharmaceutically acceptable salts together with an organic acid
WO2014006636A3 (en) Stable compositions of fesoterodine
PT2722322T (pt) Derivado de 1,3-di-oxo-indeno, seu sal farmaceuticamente aceitável ou isómero ótico, seu método de preparação, e composição farmacêutica contendo o mesmo como ingrediente ativo, antiviral
WO2011161223A3 (en) Pharmaceutical oral dosage forms comprising lercanidipine and enalapril and their pharmaceutically acceptable salts
WO2013072770A3 (en) Pharmaceutical formulations comprising atorvastatin and glimepiride
WO2016126115A3 (en) Pharmaceutical composition comprising pitavastatin or a pharmaceutically acceptable salt thereof, and valsartan or a pharmaceutically acceptable salt thereof